US45719W2052 - Common Stock
Company expects to report trial results in 4Q24
Company expects to report trial results in 4Q24...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE)...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the first quarte...
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET...
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – ...
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage...
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension...
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the fourth quart...
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET...
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate...
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of...
Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer
Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer...